Table 2.
Characteristics of the patients in the included studies.
| Characteristics | Total | |
|---|---|---|
| ≥65 years | 502 | |
| Sex | Male | 1788 |
| Female | 361 | |
| Race | White | 612 |
| Asian | 465 | |
| Black | 16 | |
| Other | 15 | |
| ECOG performance status | 0 | 476 |
| 1 | 632 | |
| 2 | 7 | |
| Extrahepatic metastases | 985 | |
| Vascular invasion | 212 | |
| Child–Pugh score | A | 1261 |
| B | 128 | |
| C | 6 | |
| Baseline AFP | >200 ng/mL | 441 |
| ≤200 ng/mL | 290 | |
| Previous treatment | Surgical resection | 188 |
| Systemic therapy | 283 | |
| Sorafenib | 676 | |
| Loco-regional (TACE/SIRT/radiation) | 45 | |
| BCLC stage | B | 157 |
| C | 977 | |
| Alcohol use | 344 | |
| HBV | 640 | |
| HCV | 175 | |
Some characteristics were not available in some studies.
AFP, a-fetoprotein; ECOG, Eastern Cooperative Oncology Group; BCLC stage, Barcelona Clinic Liver Cancer stage. HBV, hepatitis B virus. HCV, hepatitis C virus.